- CEO
- Hai Jiao Wang
- Full Time Employees
- 494
- Sector
- Retail trade
- Industry
- Drugstore chains
- Address
- Building S, Kehui Jingu Guangzhou GD China 510663
- IPO Date
- Jul 9, 2024
- Business
- Fangzhou Inc. (6086.HK) operates as an investment holding company that provides online chronic disease management services in China through its Jianke Platform, focusing on patients with conditions such as hypertension, cardiovascular and respiratory diseases; the company offers comprehensive medical services including follow-up physician consultations, e-prescriptions, prescription refills and home delivery via its hospital-to-home (H2H) telemedicine platform supported by nearly 223,000 registered physicians (59% from Class III hospitals); online retail pharmacy services encompassing nearly 215,000 drug SKUs (62% prescription medications), healthcare products and pharmaceutical sales through online and minimal offline channels; wholesale of pharmaceutical products to third parties; and customized content and marketing solutions such as academic and patient community services, live streaming (over 11,000 sessions in 2024), search engine optimization, medical surveys and distributor data integration for pharmaceutical companies. Founded in 2015 and headquartered in Guangzhou, China, at Floor 1-2, 4th Street, Building S, Kehui Jingu, No. 99 Science Avenue, the company serves a platform with 49.2 million registered users and 10.1 million average monthly active users as of December 31, 2024, primarily targeting chronic disease patients and healthcare providers across China with a robust supply chain linking over 1,500 suppliers and 900 pharmaceutical firms. Fangzhou Inc. reports revenue across these segments totaling RMB2.71 billion for the year ended December 31, 2024 (up 11.2% year-over-year), with online retail pharmacy at RMB1.40 billion (8.3% growth), comprehensive medical services at RMB647 million, wholesale at RMB551 million (728.5% surge) and customized content/marketing at RMB105 million (20.7% rise); it achieved adjusted net profit of RMB17 million (up 139%) despite statutory losses from share-based compensation. Recent developments include integration with China's social healthcare insurance for online reimbursements and dual-channel prescriptions via its Qishi Internet Hospital and Fangzhou Jianke Medical Insurance Assistant Mini Program; strategic partnerships with Guangzhou Baiyunshan Pharmaceutical, Bristol Myers Squibb, Innovent Biologics, Zhejiang Otsuka Pharmaceutical and Tencent Healthcare for AI-enhanced chronic disease management; rollout of AI applications like AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant and AI-Powered Search powered by a proprietary large language model; expansion of physician recruitment via sales force automation and social CRM systems; and honors such as 2024 Guangdong AI Catalyst recognition, national high-tech enterprise status for subsidiary Fangyixing and Top 10 AI+Healthcare listing. The company employs 488 staff as of December 31, 2024, and maintains a repeat purchase rate of 84.7% among paying users, with prescription drugs comprising 81.3% of GMV.